Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis

Background: Few data exist on how ofatumumab treatment impacts SARS-CoV-2 booster vaccination response. Methods: KYRIOS is an ongoing prospective open-label multicenter study on the response to initial and booster SARS-CoV-2 mRNA vaccination before or during ofatumumab treatment in relapsing MS pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziemssen, Tjalf, Schlegel, Eugen, Groth, Marie, Ettle, Benjamin, Bopp, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223661/
https://www.ncbi.nlm.nih.gov/pubmed/37243082
http://dx.doi.org/10.3390/vaccines11050978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223661/
https://www.ncbi.nlm.nih.gov/pubmed/37243082
http://dx.doi.org/10.3390/vaccines11050978

Ejemplares similares